Evidence map›Paper›PMID 40968428›Full record

ReviewMini reviews in medicinal chemistry2025

Therapeutic Potential of Underexplored Phytoconstituents Targeting Molecular Pathways in Breast Cancer Subtypes.

Shruthi Laya Saravana Kumar, Jubie Selvaraj, Prisil Naveentha Xavier, Megha Sanjay, Antony Justin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mini reviews in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shruthi Laya Saravana KumarDepartment of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, 643 001, Tamil Nadu, India.
Jubie SelvarajDepartment of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, 643 001, Tamil Nadu, India.
Prisil Naveentha XavierDepartment of Chemistry, PSG College of Arts & Science, Coimbatore, 641 014, Tamil Nadu, India.
Megha SanjayDepartment of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, 643 001, Tamil Nadu, India.
Antony JustinDepartment of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, 643 001, Tamil Nadu, India.ORCID 0000-0002-1015-8317

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a heterogeneous disease consisting of several molecular subtypes, such as Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor 2-positive (HER2+), and Triple-Negative Breast Cancer (TNBC). Although a lot of success has been realized in targeted agents, there still remain significant problems, including resistance to drugs, toxicity related to treatment, and few therapeutic possibilities for aggressive subtypes. Confronting such limitations requires complementary treatment approaches with better efficacy and safety profiles. Phytoconstituents from natural sources have emerged as potential therapeutic agents due to their multitargeting activity, good safety profile, and capacity to evade drug resistance. These bioactive molecules, such as flavonoids, alkaloids, terpenoids, and saponins, possess various mechanisms of action, including modulation of cell cycle regulators, induction of apoptosis, inhibition of angiogenesis, suppression of metastasis, and regulation of critical oncogenic signaling pathways. Their interference with several cancer pathways gives them a holistic strategy for breast cancer therapy. This review offers an in-depth examination of new phytoconstituents that target the molecular basis of various subtypes of breast cancer. It also highlights their scope for integration into traditional paradigms either as monotherapy or in combination with current therapies to increase therapeutic impact with the least adverse effects. Through the clarification of their mechanisms of action and therapeutic advantages, this review promotes the ongoing pursuit of phytoconstituents as potential contenders in contemporary oncology, providing novel targets for the control of breast cancer and enhanced patient care.

Indexed as

Antineoplastic Agents, PhytogenicBreast NeoplasmsPhytochemicalsAnimalsFemaleHumansSignal TransductionAntineoplastic Agents, PhytogenicPhytochemicalsalkaloids.bioactive moleculesBreast cancernovel targetsoncogenic signallingterpenoids

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.